-
-
-
-
-
-
-
Biogen shares rise after Q1 beat; full-year profit outlook slashed
-
-
-
-
-
-
-
Guggenheim Reiterates Buy Rating on Biogen (BIIB) following Apellis deal
-
-
-
-
-
-
-
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
-
-
-
-
-
-
-
Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
-
-
-
-
-
-
-
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
-
-
-
-
-
-
-
Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
-
-
-
-
-
-
-
SAGE Therapeutics (SAGE) Explores Strategic Alternatives
-
1,158,072 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

